Mito's $249 Heart Scan: What a Coronary Calcium Score Actually Tells You
Mito Health now offers a $249 coronary artery calcium scan, which shows existing arterial plaque. Who the 2026 ACC/AHA guidelines say should consider one.
Best Outdoor Saunas: What to Know Before You Build (Site Prep, Foundation, and Hardwired 240V)
An outdoor sauna is a building project: site prep, foundation, a 240V circuit, and drainage come first. How to choose an outdoor sauna for your site.
Choose Your Home Sauna Heat System Before You Choose a Brand
Traditional, infrared, hybrid, and portable home saunas solve different problems. Why choosing the heat system before the brand avoids the costliest mistake.
FDA Puts Aging on Its Regulatory Science Agenda — What That Actually Means
The FDA added aging to its regulatory science agenda. It signals seriousness about longevity but creates no new trial pathway or approval. What it does mean.
Peter Attia's Framework for Prioritizing Health Interventions — What's High-Impact vs. Optimization
Peter Attia separates foundation interventions (exercise, sleep, nutrition) from optimizations like supplements, judged by effect size and trade-offs.
The Longevity Biotech 100x Return Is Real — But It's Social Value, Not Investor Profit
A model puts $366.8 trillion of social value on therapies adding 10 years of life, against $3.3 trillion in costs. Why that 100x isn't an investor return.
Peter Attia on Thyroid Health: Why 5% of Adults Are Mismanaged, TSH Isn't the Full Picture, and What to Do When Tests Look Normal But You Don't
In AMA #89, Peter Attia addresses thyroid dysfunction — one of medicine's most commonly mismanaged conditions. TSH measures pituitary signaling, not tissue-level T3 activity. He stakes out the messy middle between under-treatment and over-treatment camps, with a framework for evaluating subclinical dysfunction and persistent symptoms with normal tests.
Ultrahuman's HealthEx PowerPlug Maps 532 Medical Conditions to Your Ring Data — And Generates Doctor-Ready Visit Summaries
Ultrahuman's HealthEx PowerPlug integrates electronic medical records with Ring biomarker data — mapping 532 conditions, medications, and procedures to a unified timeline alongside heart rate, HRV, skin temperature, and sleep. Launches at $4.99/month or $45.99/year; HealthEx Wallet remains free.
Yale Tested 51 Antiaging Interventions. Only 13 Actually Worked.
A Yale University-led study published in Nature Medicine analyzed 51 human intervention studies across 3,128 blood samples using 16 epigenetic clocks and 94 DNA methylation biomarkers. Result: 51% of interventions showed no significant epigenetic age change. Senolytics failed. Anti-TNF therapies and Mediterranean diet protocols produced genuine, reproducible effects.
Apple Watch Series 12 Can Now Estimate Your Biological Age. Here's What It Actually Measures.
Apple Watch's new Longevity tab introduces a Health Age metric built from VO2 max, resting heart rate, sleep quality, and HRV — plus optional lab inputs. The hardware update delivers 24x faster HRV refresh and splits HRV into two clinically distinct signals.
Screens Aren't Causing the Myopia Epidemic. The Real Culprit Is What They're Replacing.
Peter Attia reviews the evidence on rising nearsightedness rates and finds screens are a weak causal factor — the real driver is reduced outdoor time and the loss of bright-light exposure that comes with it. 90–120 minutes outside daily is the most evidence-backed intervention.
Mito Health Hits 1 Million Lab Tests — and the $9 Membership Model Is Why It Matters
Mito Health, the direct-to-consumer diagnostics platform, has processed over 1 million lab tests at cost with a $9/month flat-fee membership. The milestone marks a shift in how serious longevity practitioners access biomarker data — no insurance, no referrals, no per-test markup.
Blood Pressure and Longevity: What Peter Attia's AMA #48 Gets Right About Measurement
Blood pressure is one of three primary drivers of atherosclerosis — yet most people check it once a year. Attia's AMA #48 rebroadcast makes the case for treating it as a daily metric.
Zone 2 Training: Why Time-Constrained Athletes May Be Better Off Skipping It
Peter Attia reframes Zone 2 as a volume tool, not a metabolic must-do — and the implications for busy people are bigger than expected.
Insilico Medicine's 287% Revenue Jump: AI Drug Discovery Is Becoming Real Pharma Revenue
Insilico Medicine grew to $106M revenue in H1 2026 on $7.3B in total deal value with Eli Lilly, Servier, and others — and a 90% gross margin that confirms AI drug pipelines have crossed from research promise to commercial scale.
Oura Health Files for IPO at $16 Billion: What a Smart Ring's Valuation Tells Us About Biometric Data
Oura Health is targeting a $3B raise at a $16B valuation — a 45% jump from 18 months ago — built on a hardware-plus-subscription model that turns sleep and recovery data into recurring revenue.
Mount Sinai's $1M XPRIZE Bet: Can the Immune System Be Reset to Fight Aging?
Mount Sinai secured $1M in XPRIZE Healthspan funding to run NYC-Vita, a trial combining lifestyle and medication to restore immune function decades lost to aging.
Quest Diagnostics Is Now Selling Biological Age: What the $29 Test Actually Measures
Humanity's biological age test is now a $29 add-on at 2,000 Quest locations. The model behind it tracked 306,000+ people for 11.6 years and covers six body systems.
Gum Recession: Why the Habits You Think Are Helping May Be Hurting
Gum recession affects 88% of adults 65+, and aggressive brushing is a leading cause. Why lost gum tissue never grows back — and the one technique change that matters.
Tru Niagen at GNC and Sam's Club Signals NAD+ Has Left the Longevity Niche
The number one NAD+ supplement in the US is now in nearly 300 retail locations across 44 states. What the GNC and Sam's Club expansion says about where the longevity market is heading.
Whole-Body MRI Is Leaving the Biohacker Bubble
EHE Health's partnership with Prenuvo brings whole-body MRI screening into 200+ preventive care clinics. What this transition from biohacker niche to medical infrastructure means for longevity-minded members.
Wonderfeel: What a 4,235% Growth Rate Signals for the NAD+ Supplement Market
The NAD+ longevity brand ranked No. 1 biotech on the 2026 Inc. 5000. The growth rate reflects a consumer longevity market that's moving faster than most industry observers expected.
Can AI Put the Cell Back Together? GenBio's Virtual Cell Model Tries
GenBio AI's AIDO Cell system creates a stateful virtual cell model — integrating DNA, RNA, and protein behavior — to predict how intervention sequences affect biological aging.
Function Health's AI Connector: Your Lab Results Just Became AI Training Data — For You
Function's new connector links 160+ personal lab results to ChatGPT, Claude, and Perplexity. Over 80% of members have at least one biomarker outside optimal range — now AI can reason over that directly.
GDF-15 and P-Tau217: The Biomarkers That Warn You Before You Feel Anything
New biomarker research is shifting the question from 'what's wrong?' to 'what's coming?' GDF-15 as a cellular stress signal and p-tau217 for pre-symptomatic Alzheimer's risk represent a new category of early detection — but their limitations matter as much as their promise.
Biological Age Clocks: The Regulatory Reckoning Is Coming
With $3.74 billion flowing into longevity biotech in Q1 2026 alone, investors are backing biological age diagnostics that regulators cannot yet validate. The collision between capital and clinical evidence is building.
GDF-15 and P-tau217: The Biomarkers That Signal Breakdown Before You Feel It
Two biomarkers — GDF-15 for cellular stress and P-tau217 for Alzheimer's risk — can flag physiological strain years before symptoms appear. Here's what they measure, what trends reveal, and why a single reading misses the point.
Peter Attia Episode 404: Why the Neurotransmitter Model of Mental Health Is Incomplete
Dr. Linus Abrams argues that psychiatry's focus on symptom reduction through medication overlooks the hormonal, metabolic, and inflammatory drivers of mental health. The implications for how practitioners and patients think about mental wellbeing are significant.
The Antiaging Trial That Just Won $1M From XPRIZE to Test in Humans
AgelessRx has been selected as one of 10 Milestone 2 awardees in the $101M XPRIZE Healthspan competition, earning $1M to advance a one-year randomized trial testing a six-component antiaging protocol including low-dose rapamycin, NAD+, and metformin.
Menopause Is a Muscle-Health Inflection Point — and Most Programs Miss It
Estrogen decline during menopause narrows the window for muscle protein synthesis and changes how training responds. The intervention stack is specific: protein distribution, progressive resistance, and individualized HRT consideration — not just more of each.
5 Perimenopause Supplements That Actually Hold Up: Evidence-Graded and Label-Checked
Most perimenopause supplement blends are under-dosed marketing. This evidence-graded breakdown identifies five options that hold up on clinical data, labeled doses, and standardized extracts.
5 Perimenopause Supplements That Hold Up: Evidence-Graded and Label-Checked
Most perimenopause supplement blends are underdosed and opaque. This evidence-graded breakdown applies clinical trial dosing standards to the current field — here are the five that survive scrutiny.
Blood Filtering Is the New Wellness Flex — And Viome Just Bought the Infrastructure
Viome's acquisition of Circulate Health pairs multi-omics biomarker testing with therapeutic plasma exchange. What this convergence means for longevity-focused consumers navigating an increasingly clinical wellness stack.
Peptides: Peter Attia's Framework for Separating Science from Marketing
Peter Attia's episode #403 gives biohackers a rigorous 5-question test for evaluating peptides — and most gray-market compounds fail at question one.
Healthy Aging: Why Exercise Is Non-Negotiable and Protein Is Supporting Cast
New research reframes the protein-first aging model. Exercise is the irreducible core of healthy aging — protein helps, but it doesn't replace what movement does at the cellular level.
Protein Restriction for Kidney Disease: What the Evidence Actually Shows
Peter Attia reviews the MDRD trial and Cochrane data: the default CKD advice to restrict protein lacks the evidence base it's been given — and the biggest trial showed higher long-term mortality in the restriction group.
Aging Research Has Been Studying the Wrong Sex
The Reproductive Resilience Hypothesis, published in Cell, argues female biology holds the key to understanding longevity — but most aging research has treated it as experimental noise.
One Shot, Five Organs: FGF21 Gene Therapy Extends Mouse Healthspan by 20%
A single AAV injection of FGF21 extended median lifespan by over 20% in aged mice, protecting liver, kidneys, heart, muscle, and brain — and it worked after age-related decline had already begun.
Human Longevity's $599 Genomics for All: What Clinical-Grade DNA Sequencing Gets You Now
Human Longevity sequences all 6.4 billion base pairs at $599 — and an AI layer re-alerts you as science evolves. What it covers, who it's actually for, and why the re-analysis matters more than the price.
The Bathroom as a Longevity Clinic: What Vivoo's Passive Monitoring Stack Changes
Vivoo's urinalysis platform and toilet-integrated hydration monitor embed daily biomarker collection into existing routines. What it covers, why passive beats active testing, and where this sits in a complete longevity stack.
Living Near a Data Center Without Wrecking Your Sleep
Data centers bring measurable noise, EMF, heat, and air exposure to nearby homes. A practical framework for measuring and mitigating each risk.
Timeline Wins $5.3M Judgment Against Fake Urolithin A Sellers
A federal court awarded Timeline $5.3M and permanent injunctions against 19 counterfeit urolithin A sellers — a case that signals the longevity supplement market is finally getting real enforcement.
Ultrahuman's Emerald Update Answers a Question Wearables Kept Ignoring
Ultrahuman's Emerald overhaul replaces spreadsheet-style metrics with a decision engine that tells you what to actually do next — plus a VO2 max algorithm validated to lab-grade accuracy.
Peter Attia's Framework for Environmental Threats to Longevity: Air, Noise, and Light
AMA #87 applies Attia's 80/20 principle to chronic environmental exposures — PM2.5, noise, and artificial light — and which interventions actually move the longevity needle.
Dumbo Health Is Turning Sleep Into a Clinical Longevity Metric — Here's What That Means
Miami-based Dumbo Health launched Sleep Longevity: 51 blood biomarkers, wearable data, and physician care in one membership. The 90% of women with undiagnosed sleep apnea are the real target.
Scientists Reversed 'Permanent' Aging Damage in Human Tissue. Here's What Was Fixed.
A Nature Communications study showed an engineered enzyme (CMLase) removed advanced glycation end products from human arterial, skin, and lens tissue — reversing damage long considered irreversible.
Google's SensorFM: What a 1-Trillion-Minute Wearable Dataset Changes
Google's new foundation model for wearable sensors outperformed prior models on 34 of 35 health tasks — and what it means for the future of passive health monitoring.
Does Losing Sleep Mean Losing Lifespan? What the Meta-Analysis Can't Tell You
A new 79-study meta-analysis links short sleep to 14% higher mortality — but Peter Attia identifies a fundamental problem with the data. Here's what the observational evidence actually proves, and what the controlled research says instead.
The $10 Billion Probiotic Problem: What the Evidence Shows and What Works Instead
The probiotic market generates $10 billion per year despite evidence that most commercial supplements don't persist in the gut. Here's what the studies say—and five mechanistically stronger alternatives.
RLT Home TotalSpectrum Panels: Lab-Tested 7-Wavelength Review (2026)
A spectrometer test of RLT Home's ELITE panel measured 70.75 mW/cm² irradiance and 0.7 mG EMF at 12 inches, strong numbers for a full-body panel.
Home Infrared Sauna Buying Guide: The Three Specs That Actually Matter
The infrared sauna market spans $200 blankets to $15,000 cabins. Most buyers choose wrong by focusing on wood and aesthetics. Three specs determine whether a unit delivers results.
Fountain Life's $595 BASE Plan Is the Longevity Industry's Mass-Market Moment
Fountain Life's new BASE membership brings 100+ biomarkers, DEXA scan, and AI-guided clinician review to individuals for $595 — a significant shift from its ultra-premium roots.
C15:0: The Saturated Fat That Longevity Researchers Are Rethinking
Pentadecanoic acid — an odd-chain saturated fatty acid — is showing geroprotective properties that challenge blanket warnings against saturated fat, with initial research from Navy dolphin aging studies.
SystemAge 2.1: The First Biological Age Test with Separate Male and Female Models
Generation Lab's SystemAge 2.1 analyzes 460+ biomarkers across 21 organ systems using gender-specific algorithms — the most granular biological age measurement now available through clinical partners.
GARM's Klotho Longevity Residency Brought 22 Participants to Honduras. Here's What They're Testing.
A four-day longevity residency at the Kimpton Grand Roatán included a proprietary Klotho intervention, blood sampling before and after, and researchers from MIT and Harvard. GARM is betting that Klotho is the next longevity biomarker to watch.
Peter Attia: High HDL Cholesterol Doesn't Protect Your Heart. It Might Hurt It.
HDL-C has been called 'good cholesterol' for decades. Peter Attia's latest analysis unpacks why the clinical evidence never supported the label — and why very high HDL-C levels may signal elevated cardiovascular risk, not lower.
Lung Cancer Screening for Never-Smokers: What the Data Says
Guidelines don't recommend lung cancer screening for never-smokers — but the evidence gap is a policy artifact, not a scientific finding. Peter Attia makes the case for personalized assessment.
Rapalogix: $20M to Bring Rapamycin Anti-Aging Science to Skincare
Rapalogix Health raised a $20M Series A to expand rapamycin-based skincare targeting TORC1 — the cellular pathway behind systemic longevity interventions, now applied topically.
Menopause Tracking: Why the Average Is 9 Symptoms, Not 1 or 2
A Winona study of 100,000+ women found an average of nine simultaneous menopause symptoms — and 77.5% waited over a year before accessing care. The data reframes how practitioners should think about this life stage.
Your Complete Genome for $599: Human Longevity Inc. Bets on Consumer Genomics
Human Longevity Inc. now offers full whole-genome sequencing for $599 — down from ~$10,000 a decade ago — bundled with AI-powered multi-omics analysis across more than 50,000 conditions.
Ultrahuman M2 Live Makes Continuous Glucose Monitoring Mainstream
Ultrahuman's M2 Live pairs with Abbott's OTC Lingo CGM to bring prescription-free glucose tracking to anyone for $99/month — removing the biggest barrier to metabolic health monitoring.
Why Smart People Believe Bad Health Advice: The Cognitive Bias Map
Intelligence doesn't protect against health misinformation — it often amplifies it. Here's the framework for recognizing which cognitive traps are most likely to corrupt your health decision-making.
Forever Chemicals Are Accelerating Your Biological Age — Longevity Needs to Catch Up
Two peer-reviewed studies link PFAS exposure to accelerated epigenetic aging via C-reactive protein. The longevity field's focus on what to add ignores what to remove — and that gap is measurable.
Elysium Creatine+: A Three-Ingredient Stack Targeting Strength, Recovery, and Longevity
Elysium Health's new Creatine+ combines creatine monohydrate with HMB and pomegranate-derived urolithin A precursors — a longevity-focused formulation co-developed with a Stanford longevity researcher.
Geroscience Is Rewriting the Logic of Disease Prevention
Thirty percent of centenarians escape major age-related disease entirely — not by treating conditions as they arrive, but by aging differently. Geroscience targets the shared biological mechanisms underlying multiple diseases simultaneously. Here's where the clinical evidence stands in 2026.
The Breast Cancer Screening Framework Peter Attia Uses — And Why Standard Mammogram Advice Falls Short
Risk-stratified screening starts with a formal risk assessment by age 25 — not when your doctor first orders a mammogram at 40. Peter Attia's framework explains why, and what the implementation failure actually looks like at scale.
The World's First Human Kidney Regeneration Surgery Is Scheduled for July 2026
Rokit Healthcare has clinical approval to begin the first human kidney regeneration trial using AI-assisted 3D bioprinting and robotic surgery with the patient's own omentum-derived cells — a milestone that sidesteps transplant waiting lists entirely.
China Launches the World's First 2,000-Person Stem Cell Antiaging Trial
Beijing's 301 Hospital is running the largest stem cell trial ever attempted for aging prevention, shifting longevity science from disease treatment toward systemic intervention.
Immorta Bio's Combination Therapy Reports 70%+ Lifespan Extension in Animal Models
A peer-reviewed study combining senolytic immunotherapy with stem cell regeneration shows dramatic lifespan gains. What the animal data does and doesn't tell us.
Biological Optionality: Why Freezing Your Younger Cells Now Is a Bet on Future Medicine
Acorn Biolabs harvests mesenchymal stem cells from hair follicles and cryopreserves them—banking the secretome of a healthier version of you against therapies that don't exist yet.
Plasma Exchange Cuts Blood Microplastics by 60%: First Clinical Data
A May 2026 study in the Journal of Clinical Apheresis found therapeutic plasma exchange reduced blood microplastic levels from 52.2 to 21.1 particles per 100µL — the first peer-reviewed data on clinically removing microplastics from circulation.
Elysium Health Launches Physician-Led Longevity Program — Moving From Supplements to Clinical Care
Elysium's new Elysium Longevity Institute combines NAD+ protocols, peptides, and longitudinal data tracking under physician oversight. The shift signals a broader move in longevity from consumer supplementation to integrated clinical programs.
Peter Attia's Three-Question Framework for Cutting Through Supplement Noise
Peter Attia's AMA #85 framework for supplement evaluation: define the problem precisely, measure with a biomarker, and weigh risk against reward honestly.
Biohacking's Biggest Surprise: The Average Practitioner Is Over 65
The largest age group in biohacking is 65+, most practitioners spend under $500/month, and strength training beats peptide therapy 2:1.
Glycans: The Aging Biomarker That Predicts Disease a Decade Early
IgG glycans explain 58% of age variance—more than telomeres—and predict cardiovascular events and diabetes onset up to 10 years early. Here's what that means.
Ossium Health: The Case for Rebuilding the Immune System From Scratch
PRESERVE I trial: all 4 patients achieved full donor chimerism and remained relapse-free at Day 180 using banked deceased-donor bone marrow. What this means for longevity.
Fasting as Regenerative Medicine: What the FMD Data Actually Shows
Dr. Valter Longo's clinical trials show fasting-mimicking cycles reduce biological age by 2.5 years and helped 60-70% of diabetes patients reduce medications. The mechanism isn't weight loss.
APOE2: The Gene That Supercharges Your Neurons' DNA Repair
Buck Institute research links APOE2 to measurably lower neuronal senescence and stronger DNA repair — the mechanism behind why APOE2 carriers resist Alzheimer's disease.
Rapamycin + Exercise: Why the First Real Trial Disappointed
Rapamycin may blunt exercise gains in older adults. Peter Attia: this trial is underpowered—but the HbA1c signal is real.
Muscle as Medicine: Why Strength Is the Missing Variable in Longevity
When 40% of weight-loss drug results come from muscle, health outcomes worsen. Here's why strength — not scale weight — is the longevity lever that determines outcomes.
Your Immune System Can Now Have a Digital Twin — Here's What That Means
A Zurich clinic and Barcelona AI firm just launched the first commercial immune digital twin platform. It's early-stage, but the model it represents is where preventive health is heading.
60% of Workers Rank Health Access First. Employers Are Behind.
A new UK survey finds 60% of workers rank health insurance above all other benefits — a signal that healthspan is reshaping what employees expect from employers.
Hone Health + BodySpec: Clinical DEXA Inside Your Longevity OS
Hone Health and BodySpec integrate clinical DEXA scans into a longevity OS, moving bone composition data from reactive diagnosis to preventive care.
Longevity Quotient: When a Clinical Score Meets Continuous Wearable Data
Agentis Longevity integrates Ultrahuman's Ring AIR and M1 CGM into its Longevity Quotient — giving a five-component clinical score a real-time wearable data layer.
Ultrahuman Wearables Now Power a Living Longevity Score
Agentis and Ultrahuman link real-time ring and CGM data to the Longevity Quotient — a living composite score that tracks where your health trajectory is heading.
Cataracts and Dementia Risk: The Surprisingly Simple Brain-Protection Lever
A meta-analysis of 558,276 participants finds cataract surgery associated with 25% lower dementia risk. Vision correction may be one of the most accessible cognitive interventions in aging.
Portable Red Light Therapy Devices in 2026: A Tiered Buyer's Guide
The home RLT market hit $1.2B and is growing at 59% annually. What the numbers don't show: major capability gaps between $295 portable panels and $549 wearable devices.
Peter Attia AMA #82: From Longevity Theory to Real-World Practice
AMA #82 shifts from mechanism to application — DEXA interpretation, wearables use, stability training, and the habits that actually stick for patients in their 40s through 60s.
NLRP3: The Inflammasome Switch Linking Aging to Chronic Disease
NLRP3 links obesity, Alzheimer's, and aging through a single inflammasome. Suppressing it extended mouse lifespan 34%. Q2 2026 clinical trial data is due.
VITAL-H: The $38M Trial Testing Rapamycin, Ozempic, and Farxiga Against Aging
A federally funded trial at UT Health San Antonio is testing three FDA-approved drugs in 726 healthy adults aged 60–65 to see if aging itself can be slowed with existing medications.
ZEUGMA Hyperbaric Chamber: When HBOT Becomes a Longevity Engineering Tool
HPO.TECH's ZEUGMA chamber takes hyperbaric oxygen therapy from clinical setting to performance optimization — dissolving oxygen directly into plasma at 2.4 ATA for recovery and longevity.
One Man's Alzheimer's Mutation Isn't Causing Dementia. Heat Shock Proteins May Be Why.
A 75-year-old with a dominant Alzheimer's mutation remains cognitively healthy. Heat shock proteins may explain why — and what it means for brain longevity research.
Why Your Biohacking Stack Isn't Working: The Context Problem
The reason most health interventions fail isn't the intervention — it's the absence of a personalized model of how your biology actually responds.
Gamma-Band Modulation: The Hardware-Software Convergence in Cognitive Longevity
Analyzing the Spectris platform's use of sensory-driven gamma oscillations to preserve neural architecture and cognitive function.
The Architecture of Longevity: Backcasting VO2 Max and Strength
A technical breakdown of longevity-focused benchmarks, cognitive protection via metabolic health, and the utility of geroprotective GLP-1 applications.
Intrinsic Capacity: The New Benchmark for Biohacking Architecture
Analysis of the Stanford THRIVE coalition's push for measuring intrinsic capacity at scale and its implications for longevity protocols in 2026.
The Longevity Alpha: Strength Benchmarks and VO2 Max Targets in 2026
A data-driven deep dive into the core physiological metrics that define the current architecture of human longevity.
The Longevity Protocol: Benchmarking Strength and VO2 Max for Cognitive Resilience
Analyzing the architectural requirements for lifelong physical and cognitive performance through the lens of recent longevity benchmarks.
The Performance Architecture: Longevity Optimization and Strength Benchmarks
Analyzing the latest standards in longevity optimization: VO2 max targets, strength benchmarks, and the exercise-centric defense against cognitive decline.
The Industrialization of Longevity: Clinical Rigor and the End of Biohacking Hype
Analyzing the transition from experimental biohacking to clinical validation, driven by ARPA-H funding and new FDA regulatory frameworks.
Longevity Trials and Environmental Risks: Navigating the Future of Biohacking
Exploring the breakthrough Klotho therapy trials and the emerging threat of nanoplastics in the brain.
Beyond Maintenance: The Architecture of Peak Human Performance
Exploring the shift from general health to the intentional architecture of biological performance.
The Industrialization of Personal Biology: Beyond the Quantified Self
How biohacking is shifting from hobbyist self-experimentation to a rigorous data-driven industry.
The Data-Driven Evolution: Biohacking in 2026
Exploring the shift from anecdotal wellness to rigorous, data-driven personal health optimization.